Last reviewed · How we verify
Didronel (ETIDRONIC ACID)
At a glance
| Generic name | ETIDRONIC ACID |
|---|---|
| Sponsor | Procter And Gamble |
| Drug class | Bisphosphonate |
| Modality | Small molecule |
| Therapeutic area | Bone |
| Phase | FDA-approved |
| First approval | 1977 |
Approved indications
- Heterotopic ossification
- Humoral hypercalcemia of malignancy
- Osteitis deformans
Common side effects
Key clinical trials
- Treatment of Ectopic Calcification in Fahr's Disease or Syndrome (PHASE2)
- Effect of Different Chelation Protocols on the Healing of Periapical Lesions in Teeth With Chronic Apical Periodontitis (NA)
- Evaluation of the Effects of Different Irrigation Solutions and Activation Methods on Postoperative Pain and Quality of Life in Root Canal Treatment (NA)
- Effect of Different Irrigation Protocols on Postoperative Endodontic Pain and Inflammation (NA)
- Antibacterial Effect of NaOCl With Etidronic Acid in Apical Periodontitis Treatment (NA)
- Effect of Different Irrigation Solutions on Postoperative Pain and Lesion Healing (PHASE4)
- Comparing Different Single and Combination Chelating Agents on Sealer Penetration and Dentin Erosion. (NA)
- The Prevention of Systemic Ectopic Mineralization in Pseudoxanthoma Elasticum (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Didronel CI brief — competitive landscape report
- Didronel updates RSS · CI watch RSS
- Procter And Gamble portfolio CI